NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421

1.1 Everolimus, in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a non-steroidal aromatase inhibitor. Everolimus is recommended only if the company provides it with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta421

Site by Devopa
© Copyright 2019 NHS. All rights reserved.